Advertisement

Picture [iito] Männer Ballett 650x80px
Document › Details

Cellectis S.A.. (7/11/11). "Press Release: Dr. Andrew Scharenberg, M.D., to Serve as Chief Scientific Officer for Cellectis Therapeutics". Paris.

Organisations Organisation Cellectis (Group)
  Today Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)
  Organisation 2 Pregenen
Product Product genomic technology
Person Person Scharenberg, Andrew M. (Andy) (Umoja Biopharma 202011 CEO + Co-Founder before Casebia Therapeutics + Cellectis)
     


- Cellectis therapeutics, a subsidiary of Cellectis (Alternext: ALCLS) specializing in the development of therapeutic applications in genome engineering, today announced the appointment of Dr. Andrew M. Scharenberg as Chief Scientific Officer.

Dr. Scharenberg is an attending physician in Immunology at Seattle Children's Hospital, and Professor of Pediatrics and Immunology at the University of Washington. His academic laboratory is based at Seattle Children's Research Institute, and is world renowned for its work on the development of genome engineering technologies for innovative therapeutic applications.

Dr. Scharenberg is a principal investigator and codirector of the Northwest Genome Engineering Consortium (NGEC), which is focused on new approaches for treating genetic diseases. In addition, he is a cofounder and member of the Board of Director's of Pregenen Inc., a biotechnology spin-off from the NGEC, and a strategic partner of Cellectis focused on the commercial development of novel genome engineering technologies.

"We are thrilled that Andrew Scharenberg has accepted the post of Chief Scientific Officer of our therapeutic subsidiary", stated Chief Scientific Officer of the Cellectis group Frédéric Pâques. "His experience and energy will push our research teams to achieve their full potential".


About Cellectis : Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris. For further information about Cellectis, visit our website at: www.cellectis.com Follow Cellectis on twitter : http://twitter.com/cellectis


   
Record changed: 2020-11-19

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Cellectis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80




» top